GLP-1R agonists: recent advances, current gaps, and future challenges.

IF 3.9 2区化学 Q2 CHEMISTRY, APPLIED

Molecular Diversity Pub Date : 2025-04-29 DOI:10.1007/s11030-025-11195-6

Anukriti Saran, Riya Raisinghani, Sarvesh Paliwal, Swapnil Sharma

引用次数: 0

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) emerged as a promising class of drugs and have been shown to be effective as a key regulator in managing glucose metabolism-associated diseases such as type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), cardiovascular effects, nephrological complications, diabetes, non-alcoholic fatty liver (NAFLD), as well as to control obesity. A few drugs included in GLP-1RA class are liraglutide, exenatide, and semaglutide. Most recent drug that is available in both oral and subcutaneous forms is semaglutide. Available, withdrawn, and investigational GLP-RAs are listed in this paper. This review article will also explore common side effects and safety profiles of both long-acting and short-acting GLP-1 RAs. Additionally, it will highlight the recent advances and ongoing challenges in the field of drug discovery related to GLP-1 receptor agonists.

查看原文本刊更多论文

GLP-1R激动剂：最新进展、当前差距和未来挑战

胰高血糖素样肽-1受体激动剂（GLP-1RAs）是一类很有前途的药物，已被证明是有效的葡萄糖代谢相关疾病的关键调节剂，如2型糖尿病（T2DM）、慢性肾病（CKD）、心血管效应、肾病并发症、糖尿病、非酒精性脂肪肝（NAFLD），以及控制肥胖。GLP-1RA类药物包括利拉鲁肽、艾塞那肽和西马鲁肽。最近口服和皮下两种形式的药物是西马鲁肽。本文列出了可用的，已撤回的和正在研究的GLP-RAs。这篇综述文章还将探讨长效和短效GLP-1 RAs的常见副作用和安全性。此外，它将重点介绍与GLP-1受体激动剂相关的药物发现领域的最新进展和面临的挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Diversity 化学-化学综合

CiteScore

7.30

自引率

7.90%

发文量

219

审稿时长

2.7 months

期刊介绍： Molecular Diversity is a new publication forum for the rapid publication of refereed papers dedicated to describing the development, application and theory of molecular diversity and combinatorial chemistry in basic and applied research and drug discovery. The journal publishes both short and full papers, perspectives, news and reviews dealing with all aspects of the generation of molecular diversity, application of diversity for screening against alternative targets of all types (biological, biophysical, technological), analysis of results obtained and their application in various scientific disciplines/approaches including: combinatorial chemistry and parallel synthesis; small molecule libraries; microwave synthesis; flow synthesis; fluorous synthesis; diversity oriented synthesis (DOS); nanoreactors; click chemistry; multiplex technologies; fragment- and ligand-based design; structure/function/SAR; computational chemistry and molecular design; chemoinformatics; screening techniques and screening interfaces; analytical and purification methods; robotics, automation and miniaturization; targeted libraries; display libraries; peptides and peptoids; proteins; oligonucleotides; carbohydrates; natural diversity; new methods of library formulation and deconvolution; directed evolution, origin of life and recombination; search techniques, landscapes, random chemistry and more;